Work

Figure S3 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2

Year: 2025

Type: other

Abstract: Figure S3. Sensitivity to BRAF inhibition does not correlate with fibronectin, α5β1 integrin, c-MET, or FAK/Src levels. BRAF inhibition increases fibronectin expression and secretion, which is blocked by ERK1/2 inhibition.

DOI: 10.1158/1541-7786.30733165

Authors: Hannah M. Hicks, Nikita Pozdeyev, Sharon B. Sams, Umarani Pugazhenthi, Elise S. Bales, Marie-Claude Hofmann, Logan R. McKenna, Rebecca E. Schweppe

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4416764810

Cites:

Cited by:

Related to: 10